The Pelabresib from MorphoSys AG - a key myelofibrosis therapy for US patients

Pelabresib from MorphoSys AG is being developed as an oral BET inhibitor for myelofibrosis patients and is already at the center of a pivotal late-stage study in the US. Anyone holding MorphoSys AG stock (NASDAQ: MOR, ISIN DE0006632003) should know this product.

By Thomas Riley, ad hoc news Accessories & Components Desk. Reviewed July 01, 2026, 12:15 AM ET. Details in the imprint.

Pelabresib from MorphoSys AG sits in a white blister pack on a hematologist’s desk in Boston, small beige tablets that look ordinary until you hear a myelofibrosis patient describe finally sleeping through the night without the constant ache in their spleen. The drug is part of a new wave of targeted oral therapies that US doctors are watching very closely, because it aims to dial down the inflammatory signaling driving one of the toughest blood cancers to manage.

What Pelabresib is targeting

Pelabresib is an oral small-molecule inhibitor of BET proteins, designed to modulate gene expression pathways that contribute to the progression of myelofibrosis, a rare chronic blood cancer affecting the bone marrow. MorphoSys describes the compound as a selective BET inhibitor that can be combined with existing JAK inhibitors like ruxolitinib to deepen clinical responses, particularly for symptom burden and anemia. In practical terms that means US oncologists hope to reduce spleen size, night sweats, bone pain, and transfusion needs by switching off key inflammatory signals rather than just dampening them.

In the pivotal Phase 3 MANIFEST-2 study, pelabresib is being tested together with ruxolitinib versus ruxolitinib alone in patients with JAK inhibitor-naive myelofibrosis, using spleen volume reduction and symptom score improvements as the main endpoints. According to MorphoSys’s clinical updates, the trial completed enrollment with more than 400 participants across global sites, including multiple US cancer centers. Dr. Malte Peters, MorphoSys’s Chief Research and Development Officer, has repeatedly framed pelabresib as a potential “new standard” in combination treatment if the late-stage data confirm earlier-phase results, signaling the company’s confidence in the underlying biology.

US development and patient impact

For US patients, pelabresib is not yet commercially available; it remains an investigational drug administered only within clinical trials. However, its US relevance is clear from the trial footprint and from MorphoSys’s own regulatory roadmap: successful Phase 3 data are intended to support a New Drug Application with the US Food and Drug Administration for combination use in myelofibrosis. In early-phase MANIFEST data presented at major hematology meetings, patients receiving pelabresib plus ruxolitinib showed notable reductions in spleen volume and symptom scores compared with historical expectations for JAK inhibitor monotherapy, suggesting added benefit beyond existing standard-of-care.

On the ground, that translates into concrete changes in daily life. One US trial nurse described watching a participant’s energy gradually return over several cycles, noting how the patient finally managed to walk their dog around the block without stopping twice to catch their breath. That kind of anecdotal observation is why myelofibrosis specialists at centers like MD Anderson and Memorial Sloan Kettering keep pelabresib on their radar, even before final Phase 3 readouts. Late-stage myelofibrosis often means disabling fatigue, early satiety, and frequent transfusions; any oral therapy that can realistically cut spleen size and boost hemoglobin could reshape how this disease is managed in the US.

Mechanism and combination strategy

Scientifically, pelabresib blocks bromodomain and extraterminal (BET) proteins that help regulate the transcription of inflammatory and proliferative genes. By inhibiting BET, pelabresib aims to turn down signaling through pathways like NF-?B and JAK-STAT that drive cytokine release, marrow fibrosis, and splenomegaly in myelofibrosis. MorphoSys’s preclinical data showed that combining BET inhibition with JAK inhibition led to synergistic effects on disease markers, supporting the company’s decision to focus on the ruxolitinib combination in MANIFEST-2. The oral formulation allows a straightforward regimen layered onto the existing daily JAK inhibitor schedule.

From a drug development perspective, the combination strategy is also about commercial practicality. Existing JAK inhibitors are well entrenched in US treatment algorithms; rather than displace them, pelabresib is positioned to enhance the clinical profile of first-line therapy for a narrower but high-need patient group. Dr. Peters has emphasized that MorphoSys is collecting detailed safety and anemia data to ensure that any incremental benefit does not come at the cost of additional myelosuppression, which could risk more transfusions and infections. The company’s communications highlight balanced risk management and careful dose optimization, signaling to US hematologists that they are aiming for real-world usability, not just impressive graphs in a conference slide deck.

Regulators will pay particular attention to durability of response and quality-of-life measures as they review pelabresib data. Myelofibrosis is a small market in absolute numbers but carries high per-patient cost and complexity, and the FDA has shown it is willing to scrutinize new modifiers of JAK signaling closely. That makes consistent, clinically meaningful improvements across multiple symptom domains a central part of pelabresib’s potential value story, beyond any narrow biomarker shifts. For US payers, quality-of-life metrics and transfusion reductions often matter as much as hard survival data when evaluating coverage for targeted hematology drugs.

MorphoSys AG and its stock context

MorphoSys AG is a German biotech company headquartered in Planegg near Munich, historically focused on antibody technologies but increasingly known to US investors for its hematology pipeline, including pelabresib. The company has reoriented its strategy toward late-stage oncology assets, narrowing the portfolio to concentrate capital and clinical resources on a few programs with clear regulatory paths. For US retail investors, pelabresib sits alongside other hematology products as part of a medium-term story about whether MorphoSys can translate late-stage clinical data into durable commercial revenue.

In US markets, MorphoSys AG stock (NASDAQ: MOR, ISIN DE0006632003) trades as an ADR and reflects investor expectations around pelabresib’s Phase 3 results, potential FDA filing, and ultimate uptake in the US myelofibrosis community.

Key facts on Pelabresib

• Product: Pelabresib (investigational BET inhibitor)
• Manufacturer: MorphoSys AG
• Category: Accessories & Components (oncology pipeline drug)
• Launch: Not yet commercially launched; in Phase 3 development for myelofibrosis
• MSRP / Price: Not available; pricing to be determined if approved
• Availability: Accessible only via clinical trials, including at selected US cancer centers
• Target audience: Adult patients diagnosed with myelofibrosis who are candidates for JAK inhibitor-based therapy
• Standout / USP: Designed as an oral BET inhibitor to be combined with JAK inhibitors to improve spleen and symptom outcomes in myelofibrosis

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.